N/A N=205 Depression Attention for Women Now (The DAWN Study)
Depressive Disorder
Primary: Depression Treatment Outcome — 0.96; 1.33 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=97 Assessing Symptomatic Clinical Episodes in Depression
Major Depressive Disorder
Primary: MADRS Score - Overall Change From Baseline — 13.7; 8.8 score on a scale — p=<.001
Phase 2 N=204 Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
Major Depressive Disorder
Primary: Change From Baseline in Hamilton Depression Rating Scale (HAMD-17) Total Score at Weeks 8 — -9.0; -7.4 Scores on a scale — p=0.121
N/A N=9 European Deep Brain Stimulation (DBS) Depression Study
Depressive Disorder, Major
Primary: Mean Percent Change From Baseline in MADRS Score — -7.7; -7.4; -8.8; -6.2 percentage change from baseline
Phase 4 N=53 Effects of Treatment on Decision-making in Major Depression
Major Depressive Disorder · Healthy Controls
Primary: Money Earned — 23.2; 25.0; 20.5; 21.9 US Dollars
Phase 4 N=85 Advancing Personalized Antidepressant Treatment Using PET/MRI
Depression
Primary: Change From Baseline in Hamilton Depression Rating Scale at 8 Weeks — 11.81; 9.41 score on a scale
Phase 3 N=598 Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of…
Phase 2 N=15 ANC-501 in the Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Mean Change From Baseline (Day 1) to Day 56 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score. — -17.5 score on a scale
Phase 3 N=1,149 A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Phase C: Time-to-Relapse by Any Criteria as Defined in Blinded Addendum — 63.0; 63.0 days — p=0.5100
Phase 3 N=327 A Trial of AXS-05 in Patients With Major Depressive Disorder
Depression · Major Depressive Disorder
Primary: Change in MADRS Total Score From Baseline to Week 6 — 15.91; 12.04 score on a scale — p=0.002
N/A N=26 Transcranial Direct Current Stimulation Therapy for Major Depression
Major Depressive Disorder
Primary: Clinical Response — 22 Participants
Phase 2 N=128 Clinical Study to Test a New Drug to Treat Major Depression
Depressive Disorder, Major
Primary: Change From Randomization (Week 0) Associated With GW856553 Versus Placebo at Week 6 in the Bech (6-item HAMD-17 [Hamilton Depression Rating Scale]) Score. — -6.5; -5.6…
Phase 3 N=48 Major Depressive Disorder With Mixed Features - Extension
Major Depressive Disorder
Primary: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) — 66.7 percentage of subjects
Phase 4 N=40 Predictors of Antidepressant Response
Depression
Primary: Changes in Mu-opioid Binding Potential During PET — 0.12 Binding potential ratio — p=<0.001
Phase 2 N=19 Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder
Major Depression
Primary: Model Adjusted Means for Hamilton Depression Rating Score — 20.22; 20.56 score on a scale — p=0.68
Phase 2 N=273 A Phase 2 Trial of OPC-64005 for Major Depressive Disorder
Major Depressive Disorder
Primary: Mean Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 6 of the Double-blind Treatment Period — -1.9; -1.6; -2.1; -3.9 Units…
N/A N=99 fMRI Studies of Emotional Brain Circuitry in People With Major Depression
Depression
Primary: Activations in Different Cortical Regions Caused by Emotionally Evocative Task — -0.021; 0.084; 0.021; -0.030 Voxels
N/A N=73 Drug Therapy to Treat Minor Depression
Depression
Primary: Efficacy Assessed Using the Inventory of Depressive Symptomatology - Clinician Rated (IDS-C) — -11.47; -9.35; -10.49 units on a scale
Phase 2 N=207 Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)
Adjunctive Treatment of Major Depressive Disorder
Primary: Change From Baseline to Week 5 in the HAMD-17 Total Score — 22.9; 22.0; 20.3; 20.4 score on a scale — p=0.0390
N/A N=255 Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults
Major Depressive Disorder
Primary: Change in the Beck Depression Inventory Second Edition (BDI-II) at Week Two Compared to Baseline. — 16.65; 14.36 units on a scale — p=0.056
Phase 2 N=296 Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression
Depression
Primary: Hamilton Rating Scale for Depression — 11.06; 12.52 units on a scale
Phase 4 N=480 Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Total Discontinuation - Emergent Signs and Symptoms (DESS) Score Over the First 2 Weeks of the Double-blind Phase — 4.1; 4.8; 5.3 scores on a scale
N/A N=132 Novel Neural Circuit Biomarkers of Major Depression Response to CCBT
Depression · Major Depressive Disorder · Depressive Disorder
Primary: Resting State Functional Connectivity: MDD vs Controls — .51; .65; .54 Z normalized correlation
Phase 3 N=569 A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Depressive Disorder, Major
Primary: Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8/Withdrawal — -13.9; -14.4; -12.9 Scores on a scale — p=0.853
N/A N=851 Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Percentage of Participants With Remission Based on Hamilton Depression Scale (HAM-D) — 54.4 Percentage of participants
Phase 2 N=67 Rapid Antidepressant Effects of Ketamine in Major Depression
Depression · Mood Disorders · Major Depresssion
Primary: MADRS Score - Baseline — 1.17; 1.48; 33.83; 31.82 units on a scale
Phase 2 N=504 MDD POC Study GSK372475 Subjects Depressive Disease
Depressive Disorder
Primary: Mean Change From Randomization at the End of the Treatment Phase in the MADRS Total Score — -16.9; -19.0; -20.5 Score on scale — p=0.485
Phase 3 N=211 Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Major Depressive Disorder With Mixed Features
Primary: Mean Change From Baseline to the 6-week Study Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Scores — -20.5; -13.0 units on a scale — p=<0.0001
Phase 2 N=20 Spinal Cord Stimulation for the Treatment of Major Depressive Disorder
Major Depressive Disorder
Primary: Montgomery Asberg Depression Rating Scale (MADRS) Score Change — -21.7; -14.6 summed total scores — p==0.040
Phase 2 N=769 Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score. — -8.20; -7.02…